Peptide Therapy Cost UK 2026: Complete Pricing Breakdown

If you qualify for peptide-based medications through the NHS, this is by far the most cost-effective route. The UK's devolved healthcare systems mean costs vary by nation.

England — standard prescription charges (2026): - £9.90 per prescription item — this flat rate applies regardless of the medication's actual cost (a month's supply of Wegovy that costs the NHS several hundred pounds still costs the patient £9.90) - Prescription Prepayment Certificate (PPC): £31.25 for 3 months or £111.60 for 12 months — this caps your costs if you have multiple regular prescriptions - With a 12-month PPC, your effective annual cost for any peptide medication is capped at £111.60

Scotland: All NHS prescriptions are free — no charges regardless of the medication.

Wales: All NHS prescriptions are free since 2007.

Northern Ireland: All NHS prescriptions are free since 2010.

Exemptions in England (free prescriptions): - Patients with diabetes mellitus (including those on GLP-1 agonists for diabetes) receive a medical exemption certificate - Aged 60 or over - Under 16, or under 19 in full-time education - Pregnant or within 12 months of giving birth - Certain other medical conditions (hypothyroidism, hypoparathyroidism, etc.) - Income-based exemptions (Universal Credit, Income Support, etc.)

Important caveat: While the prescription charge is low, accessing these medications through the NHS can be challenging. Weight management medications like Wegovy require referral to Tier 3 specialist services, and waiting lists can be lengthy. The cost saving must be weighed against the time investment in navigating NHS pathways.

What the NHS actually pays: For context, the NHS list price for a month's supply of Wegovy at maintenance dose is approximately £200–250, and Mounjaro ranges from £100–200 depending on dose. These costs are borne by the NHS, not the patient — which is why NICE conducts rigorous cost-effectiveness appraisals before recommending these medications for NHS use.

Private prescriptions for weight loss injections represent the largest segment of the UK peptide therapy market. Here is a comprehensive breakdown of what you can expect to pay.

Wegovy (semaglutide 2.4 mg): | Dose (escalation) | Approximate monthly cost | |---|---| | 0.25 mg (weeks 1–4) | £150–200 | | 0.5 mg (weeks 5–8) | £160–220 | | 1.0 mg (weeks 9–12) | £180–250 | | 1.7 mg (weeks 13–16) | £200–280 | | 2.4 mg (maintenance) | £220–300 |

Mounjaro (tirzepatide): | Dose | Approximate monthly cost | |---|---| | 2.5 mg (initiation) | £130–170 | | 5.0 mg | £140–200 | | 7.5 mg | £160–220 | | 10 mg | £180–250 | | 12.5 mg | £200–260 | | 15 mg (maximum) | £220–280 |

Saxenda (liraglutide 3.0 mg): - Monthly cost at maintenance dose: £180–250 - Saxenda pens each contain 18 mg (enough for 6 days at maintenance dose, so approximately 5 pens per month)

Key factors affecting price: - Pharmacy/clinic markup: Different providers apply different margins. Online pharmacies tend to have lower overheads and therefore lower prices - Consultation fees: Some services charge separately for consultations (£50–150 per appointment), while others bundle this into the medication cost - Subscription models: Several providers now offer monthly subscription packages that include medication, consultations, and monitoring at a fixed price - Dose level: Higher doses cost more, which means costs increase during the escalation phase and remain higher for patients who need maximum doses

Cost-saving strategies: - Compare prices across multiple registered providers — there is genuine price variation - Ask about subscription or package deals for ongoing treatment - Consider starting with Mounjaro, which tends to be slightly less expensive than Wegovy at equivalent efficacy levels - Some providers offer loyalty discounts or referral credits - Check whether your private health insurance covers weight management pharmacotherapy (a growing number of policies now do)

Beyond the cost of the medication itself, private peptide therapy involves consultation and monitoring fees that can add significantly to the total cost.

Initial consultation fees by provider type:

Consultant endocrinologist: - In-person initial consultation: £250–400 - Follow-up appointments: £150–250 (typically every 3–6 months) - Best for: growth hormone deficiency assessment, complex hormonal issues, diabetes management

Private weight management physician: - In-person initial consultation: £100–200 - Follow-up appointments: £75–150 (typically monthly for the first 3 months, then quarterly) - Best for: weight management with GLP-1 agonists, metabolic health assessment

Online telemedicine services: - Initial consultation: £0–50 (often included in medication cost) - Follow-up consultations: £0–30 (often included in subscription) - Best for: straightforward weight management prescriptions, convenient ongoing support

Blood tests and monitoring:

| Test | Private lab cost | Notes | |---|---|---| | Full blood count | £30–50 | Baseline and periodic | | HbA1c | £20–40 | Diabetes monitoring | | Liver function | £30–50 | Recommended at baseline | | Kidney function | £30–50 | Recommended at baseline | | Thyroid function | £40–70 | If symptoms suggest issues | | Lipid profile | £30–50 | Cardiovascular risk | | Comprehensive metabolic panel | £80–150 | All-in-one option | | IGF-1 (growth hormone assessment) | £40–70 | For GH-related therapy |

Tips for reducing monitoring costs: - Ask your NHS GP whether they can run baseline blood tests before you start private treatment — many will do so - Some private clinics include blood tests in their package price - Home blood test kits from accredited laboratories (e.g., Medichecks, Thriva) can be more affordable than clinic-based tests - If you are on a shared-care arrangement, your GP may continue monitoring blood tests on the NHS even while you are on a private prescription

Growth hormone (somatropin) therapy is among the most expensive peptide-based treatments available, reflecting both the complexity of the molecule and the rigorous diagnostic process required.

NHS route (for diagnosed growth hormone deficiency): - Diagnosis requires specialist endocrinology assessment and stimulation testing - If GH deficiency is confirmed, somatropin is prescribed on NHS — patient pays only standard prescription charges (£9.90/item in England, free in devolved nations) - The NHS cost per patient is approximately £3,000–8,000 per year depending on dose, but this is borne by the NHS - NICE Technology Appraisal (TA64) guides NHS prescribing of somatropin in adults

Private route: - Endocrinologist consultation for diagnosis: £250–400 initial, plus testing costs - GH stimulation tests (insulin tolerance test or alternatives): £200–500 privately - Somatropin medication costs: - Low dose (0.2–0.4 mg/day): £300–500/month - Standard dose (0.4–0.8 mg/day): £500–800/month - Higher dose: £800–1,200/month - Annual private costs including medication and monitoring: £5,000–12,000

Brands available in the UK: - Genotropin (Pfizer) - Norditropin (Novo Nordisk) - Omnitrope (Sandoz — biosimilar, often slightly less expensive) - Saizen (Merck)

Important note on growth hormone secretagogues: Some people turn to growth hormone secretagogues (sermorelin, ipamorelin, CJC-1295, MK-677/ibutamoren) as more affordable alternatives to somatropin. However: - Sermorelin was previously available as a licensed medication but has been withdrawn from the UK market - Ipamorelin, CJC-1295, and other secretagogues are research-only compounds with no MHRA approval - MK-677 is technically a non-peptide growth hormone secretagogue and is also unlicensed - None of these can be legally prescribed by a UK doctor - The cost of research-grade secretagogues (approximately £30–80/month from research suppliers) is dramatically lower than pharmaceutical somatropin, which partly explains their appeal despite the lack of regulatory approval

For completeness, this section covers the typical costs of research-grade peptides from UK-based suppliers. These are sold as research chemicals, not for human consumption, and are not subject to pharmaceutical pricing structures.

Typical UK research peptide pricing (2026):

| Peptide | Typical quantity | Approximate price | |---|---|---| | BPC-157 | 5 mg vial | £20–40 | | TB-500 (Thymosin Beta-4) | 5 mg vial | £25–45 | | Sermorelin | 5 mg vial | £25–50 | | Ipamorelin | 5 mg vial | £20–40 | | CJC-1295 (with DAC) | 5 mg vial | £25–50 | | CJC-1295 (without DAC) | 5 mg vial | £20–40 | | GHK-Cu | 50 mg vial | £15–30 | | Melanotan II | 10 mg vial | £15–30 | | PT-141 | 10 mg vial | £20–40 | | Semaglutide (research) | 5 mg vial | £40–80 | | Tirzepatide (research) | 5 mg vial | £50–100 |

Additional costs for research peptides: - Bacteriostatic water: £5–15 per 10 ml vial (required for reconstitution) - Insulin syringes: £5–15 for a box of 100 - Alcohol swabs: £3–8 for a box of 100 - Sharps bin: £3–10

Monthly research peptide costs (estimated): Depending on the peptide, dosing frequency, and protocol, monthly costs for research peptides typically range from £30–100 — dramatically less than pharmaceutical alternatives. However, the lower cost reflects: - No GMP manufacturing standards required - No clinical trial costs to recoup - No regulatory compliance costs - Potential variability in purity, potency, and sterility - No medical oversight or prescribing framework

Price vs. value consideration: The apparent cost advantage of research peptides must be weighed against the hidden costs of using unregulated substances: - Risk of adverse effects from impurities or incorrect dosing - No recourse if the product is defective or contaminated - Potential health consequences that could result in medical costs far exceeding the savings - No regulatory protection as a consumer

Quality indicators that may justify higher prices: - Third-party analytical testing with publicly available Certificates of Analysis (CoAs) - HPLC purity verification (look for >98% purity) - Endotoxin testing (LAL test) - Suppliers based in the UK with identifiable physical addresses - Transparent manufacturing information

This section is provided for informational purposes. We do not endorse the purchase of research peptides for self-administration. Always seek guidance from a qualified healthcare professional.

Private health insurance and tax relief can offset some peptide therapy costs, though coverage varies significantly between providers and policies.

Private health insurance: - Weight management pharmacotherapy: A growing number of UK private health insurers now cover GLP-1 agonists for weight management, though this is not yet universal. Check your specific policy — coverage may be: - Included as standard - Available as an add-on benefit - Subject to pre-authorisation and clinical criteria - Limited to a specific duration (e.g., 12 months) - Diabetes management: Most comprehensive private health insurance policies cover GLP-1 agonists when prescribed for type 2 diabetes by a specialist - Growth hormone therapy: Typically covered if diagnosed by a specialist endocrinologist with appropriate testing - Excess: Remember that insurance excesses (typically £100–500) will apply to each claim

Tax relief: - Self-employed individuals: Medical expenses directly related to your ability to work may be tax-deductible in some circumstances — consult an accountant - Company health benefits: If your employer provides private medical insurance or health cash plans that cover prescriptions, peptide medications may be included - Health cash plans: Some health cash plans (e.g., Healthshield, BHSF, Westfield Health) offer prescription refunds or specialist consultation cashback that could partially offset peptide therapy costs

Flexible spending/health savings: While the UK does not have formal Health Savings Accounts like the US, some employer benefits packages include health spending accounts or wellness budgets that may be applicable.

VAT considerations: - Prescription medications are zero-rated for VAT in the UK - Private medical consultations are exempt from VAT - Research peptides are typically subject to standard-rate VAT (20%) - This means the advertised price of research peptides may or may not include VAT — check before purchasing

This article is for educational purposes only and does not constitute financial or medical advice. Consult an accountant for tax matters and a healthcare professional for medical decisions.

Navigating the peptide therapy landscape in the UK requires balancing cost, quality, and safety. Here are practical strategies for getting the best value.

1. Start with the NHS: Even if you ultimately go private, explore NHS options first. A GP appointment is free, and if you qualify for NHS-funded treatment, your annual medication cost could be as low as £111.60 (12-month PPC in England) or completely free (Scotland, Wales, Northern Ireland).

2. Compare private providers systematically: - Get quotes from at least 3 different providers before committing - Compare total costs (medication + consultation + blood tests + follow-up), not just medication prices - Ask about what is included in the package and what costs extra - Check whether the quoted price includes delivery

3. Consider the total cost of treatment, not just monthly cost: - A medication that costs slightly more per month but produces faster results may ultimately be more cost-effective - Factor in the duration of treatment — most weight management programmes recommend at least 12 months - Include the cost of potential dose escalation (higher doses cost more)

4. Negotiate and ask about discounts: - Some clinics offer discounts for prepayment (e.g., paying 3 or 6 months upfront) - Ask about referral discounts — some services offer credits for referring friends - Enquire about loyalty pricing for long-term patients - Student and NHS staff discounts are occasionally available

5. Verify value, not just price: - The cheapest option is not always the best value - Ensure your provider includes adequate monitoring and follow-up - Check that the pharmacy dispensing your medication is GPhC-registered - Confirm the medication comes from a legitimate supply chain (not grey-market imports)

6. Maximise NHS support alongside private treatment: - Ask your GP to run baseline and monitoring blood tests even if your prescription is private - Some GPs will enter into shared-care arrangements with private prescribers, handling monitoring and repeat prescriptions on the NHS - NHS weight management support services (dietary advice, exercise programmes) can complement private pharmacotherapy

7. Plan for the long term: - Weight management medications are most effective as part of a sustained programme - Budget for at least 12 months of treatment - Factor in the cost of maintaining results after stopping medication (lifestyle support, nutritional advice)

This article is for educational purposes only and does not constitute financial advice. Prices quoted are approximate and based on market conditions at the time of writing. Always verify current pricing with individual providers.